Denali Therapeutics (NASDAQ:DNLI) Coverage Initiated by Analysts at HC Wainwright

HC Wainwright began coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a report released on Wednesday,Zacks reports. The firm issued a strong-buy rating on the stock. HC Wainwright also issued estimates for Denali Therapeutics’ Q4 2026 earnings at ($0.62) EPS, FY2026 earnings at ($1.61) EPS, Q1 2027 earnings at ($0.60) EPS, Q2 2027 earnings at ($0.59) EPS, Q3 2027 earnings at ($0.57) EPS, Q4 2027 earnings at ($0.53) EPS, FY2027 earnings at ($2.38) EPS, FY2028 earnings at ($1.77) EPS, FY2029 earnings at ($1.51) EPS and FY2030 earnings at ($0.14) EPS.

Several other equities research analysts have also recently weighed in on DNLI. UBS Group increased their price objective on shares of Denali Therapeutics from $25.00 to $34.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. Robert W. Baird set a $34.00 target price on shares of Denali Therapeutics in a report on Friday, August 7th. JPMorgan Chase & Co. started coverage on Denali Therapeutics in a report on Monday, July 13th. They set an “overweight” rating and a $29.00 price target for the company. B. Riley Financial lifted their price objective on Denali Therapeutics from $30.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, August 25th. Finally, BTIG Research restated a “buy” rating and set a $39.00 target price on shares of Denali Therapeutics in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Denali Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $36.15.

Denali Therapeutics Stock Performance

Shares of DNLI stock opened at $19.72 on Wednesday. The business’s 50 day simple moving average is $20.25 and its 200 day simple moving average is $21.26. Denali Therapeutics has a one year low of $13.75 and a one year high of $27.30. The stock has a market capitalization of $3.16 billion, a PE ratio of -11.40 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.21 and a quick ratio of 8.32.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Tuesday, November 3rd. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.64. The firm had revenue of $17.78 million for the quarter, compared to the consensus estimate of $12.67 million. During the same quarter in the previous year, the business posted ($0.74) EPS. As a group, research analysts forecast that Denali Therapeutics will post -2.70 earnings per share for the current year.

Insider Transactions at Denali Therapeutics

In other Denali Therapeutics news, insider Alexander O. Schuth sold 2,857 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the sale, the insider directly owned 281,763 shares in the company, valued at approximately $7,063,798.41. This trade represents a 1.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 9.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. bought a new stake in Denali Therapeutics during the 2nd quarter valued at $360,759,000. Dimensional Fund Advisors LP boosted its holdings in Denali Therapeutics by 13.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,692,175 shares of the company’s stock worth $51,687,000 after acquiring an additional 317,872 shares during the last quarter. ADAR1 Capital Management LLC boosted its holdings in Denali Therapeutics by 3,490.9% during the first quarter. ADAR1 Capital Management LLC now owns 1,871,455 shares of the company’s stock worth $35,932,000 after purchasing an additional 1,819,339 shares during the last quarter. Bank of America Corp DE bought a new position in shares of Denali Therapeutics in the second quarter valued at approximately $31,660,000. Finally, Defilade Capital Management L.P. grew its stake in Denali Therapeutics by 107.1% in the 1st quarter. Defilade Capital Management L.P. now owns 1,359,969 shares of the company’s stock valued at $26,111,000 after purchasing an additional 703,256 shares during the period. Institutional investors own 92.92% of the company’s stock.

Key Denali Therapeutics News

Here are the key news stories impacting Denali Therapeutics this week:

• Positive Sentiment: Denali’s Q3 earnings beat expectations, while Avlayah sales reportedly rose nearly fivefold and reimbursement coverage expanded. The company also has several pipeline catalysts approaching, giving investors reasons to focus on future growth. Zacks article
• Positive Sentiment: Morgan Stanley raised its price target to $42 and maintained an Overweight rating; Wedbush also lifted its target, to $24, with an Outperform rating. These target increases suggest those analysts see potential upside. Analyst target report
• Neutral Sentiment: HC Wainwright’s estimates project ongoing losses in the coming years, including a $0.62-per-share loss in Q4 2026, but a narrower $0.14 loss in 2030. These are analyst forecasts, not company results, and indicate that a path toward profitability may take time.
• Negative Sentiment: Despite the earnings beat, investors may weigh Denali’s continuing expected losses and valuation against its commercial growth and pipeline prospects. Yahoo Finance article

About Denali Therapeutics

Denali Therapeutics Inc is a biopharmaceutical company focused on discovering and developing therapies for patients with neurodegenerative diseases. The company’s research programs target conditions including Parkinson’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis, and lysosomal storage disorders.

Denali uses its blood-brain barrier transport technology, known as the Transport Vehicle platform, to design medicines intended to deliver therapeutic proteins and other biologic treatments into the central nervous system.